Laboratory Monitoring Before Starting ACE Inhibitors

Rationale for Pre-ACE Inhibitor Laboratory Testing

A basic metabolic panel should be obtained within 1-2 weeks prior to starting an ACE inhibitor therapy, as recommended by the American Journal of Kidney Diseases 1, 2
ACE inhibitors can affect renal function and electrolyte balance, particularly serum potassium and creatinine levels, making baseline measurements essential, according to the American Heart Association, as published in Circulation 3
Baseline laboratory values help identify patients who may be at higher risk for adverse effects, including those with markedly increased serum creatinine or elevated serum potassium, as stated by the American College of Cardiology, in the Journal of the American College of Cardiology 3, 4
Patients with very low systemic blood pressure are also at higher risk for adverse effects, as noted by the American College of Cardiology, in the Journal of the American College of Cardiology 4

Renal function and serum potassium should be assessed within 1-2 weeks after initiation of ACE inhibitor therapy, as recommended by the American Heart Association, in Circulation 3, 5
The 2025 KDOQI guidelines recommend checking changes in blood pressure, serum creatinine, and serum potassium within 2-4 weeks of initiation or increase in the dose of a renin-angiotensin system inhibitor, depending on the current GFR and serum potassium, as published in the American Journal of Kidney Diseases 1
More frequent monitoring may be warranted in high-risk patients, according to the American Journal of Kidney Diseases 2

Patients with pre-existing hypotension require closer monitoring, as stated by the American Heart Association, in Circulation 5
Patients with hyponatremia, diabetes mellitus, azotemia, or those taking potassium supplements also require closer monitoring, as noted by the American Heart Association, in Circulation 5

ACE inhibitors should be initiated at low doses, followed by gradual dose increments if lower doses have been well tolerated, as recommended by the American Heart Association, in Circulation 3, 5
Continue ACE inhibitor therapy unless serum creatinine rises by more than 30% within 4 weeks following initiation of treatment or an increase in dose, as stated by the American Journal of Kidney Diseases 1
Consider reducing the dose or discontinuing ACE inhibitor in the setting of symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, as recommended by the American Journal of Kidney Diseases 1

Failure to check baseline renal function before starting therapy, especially in high-risk patients, is a common pitfall, as noted by the American Journal of Kidney Diseases 2
Not monitoring electrolytes and renal function after initiation of therapy is another common pitfall, as stated by the American Heart Association, in Circulation 5
Starting with too high a dose in patients with compromised renal function is also a common pitfall, as noted by the American Heart Association, in Circulation 5